Approved HCV Drugs
Approved HCV Drugs
DDW 2013: Prior Non-responders Can Achieve Good SVR Rates with Boceprevir Triple Therapy
- Details
- Category: HCV Treatment
- Published on Thursday, 06 June 2013 00:00
- Written by Liz Highleyman
People previously treated with interferon-based therapy can achieve good results when retreated with boceprevir (Victrelis) triple therapy, according to final results from the PROVIDE study presented at the Digestive Disease Week meeting (DDW 2013) last month in Orlando. Prior relapsers had the best response, but even 41% of prior null responders achieved a cure.
DDW 2013: Drug Interactions May Compromise Response to Boceprevir and Telaprevir
- Details
- Category: HCV Treatment
- Published on Thursday, 30 May 2013 00:00
- Written by Liz Highleyman
Concurrent use of drugs that alter concentrations of boceprevir (Victrelis) or telaprevir (Incivek or Incivo) in the body may contribute to poor response to interferon-based triple therapy for chronic hepatitis C, according to study findings presented at the Digestive Disease Week meeting (DDW 2013) last week in Orlando.
Coverage of Digestive Disease Week 2013
- Details
- Category: HBV Treatment
- Published on Wednesday, 22 May 2013 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 2013 Digestive Disease Week annual meeting (DDW 2013) in Orlando, Florida, May 18-21, 2013.
Conference highlights include direct-acting hepatitis C drugs, new strategies for using approved HCV protease inhibitors and interferon/ribavirin, and interferon-free regimens.
HIVandHepatitis.com DDW 2013 conference section
5/22/13
DDW 2013: Viral Breakthrough May Occur during Interferon/Ribavirin 'Tail' of HCV Triple Therapy
- Details
- Category: HCV Treatment
- Published on Wednesday, 22 May 2013 00:00
- Written by Liz Highleyman
HCV viral breakthrough is an ongoing possibility during the pegylated interferon/ribavirin continuation phase after triple therapy with telaprevir (Incivek or Incivek or Incivo), especially for difficult-to-treat patients, researchers reported this week at the Digestive Disease Week conference (DDW 2013) in Orlando.
EASL 2013: Anemia Is a Common Side Effect of First-generation HCV Protease Inhibitors
- Details
- Category: HCV Treatment
- Published on Wednesday, 15 May 2013 00:00
- Written by Liz Highleyman
About half of patients taking boceprevir (Victrelis) or telaprevir (Incivek or Incivo) developed anemia and approximately one-third experienced skin rash, but sustained response rates were high in an analysis of a population representative of people with chronic hepatitis C in North America, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.
More Articles...
- EASL 2013: Triple Therapy for Hepatitis C Is Effective after Liver Transplantation but Comes with Side Effects
- EASL 2013: Triple-Drug HCV Therapy Comes with High Risk of Serious Adverse Events for Cirrhotics
- EASL 2013: Daclatasvir + Sofosbuvir Offers Rescue Therapy after Current Standard of Care
- CROI 2013: Telaprevir Triple Therapy Improves HCV Response for Black Null Responders
Web Design and Development by